Biological adaptive radiotherapy for short‐time dose compensation in lung SBRT patients

This study demonstrated that the BART framework effectively compensates for the biological dose reduction caused by interruptions during lung cancer SBRT. BART successfully maintained target dose coverage and minimized biological dose loss for the target, while keeping OAR doses within safe limits, including for the lungs and spinal cord. The introduction of BART marks a significant advancement in adaptive radiotherapy, offering a comprehensive approach to managing interruptions and improving clinical outcomes.